The Good Bug raises Rs 100 crore from Susquehanna Asia VC, Fireside

Gut health startup The Good Bug has raised Rs 100 crore (about $12 million) in a Series B funding round led by Susquehanna Asia Venture Capital, the VC arm of Susquehanna International group. Existing investor Fireside Ventures also participated in the round.

Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, the Mumbai-based company develops probiotic and gut-focused health products targeting digestion, immunity, and metabolic health.

The fresh capital will be used to ramp up R&D in microbiome science, scale clinical trials, expand distribution, and strengthen brand awareness among both consumers and healthcare professionals, Biyani told ET. “The main deployment of these funds will be towards accelerating innovation in microbiome science and bacterial research,” said Biyani. “We’ll continue investing in clinical trials, brand building, and hiring top-tier talent across research, science, and business.”


The Good Bug last raised $4 million in a Series A extension in 2024, led by Sharrp Ventures, the family office of Marico Group’s Harsh Mariwala. The latest fundraise brings its total funding to around $20 million.

In April, the startup launched Metabolically Lean, a GLP-1-based formulation marketed as a natural, non-invasive alternative to weight-loss drugs like Ozempic and Mounjaro. The company claims the product naturally boosts GLP-1 levels to curb appetite and improve metabolism.

“With strong momentum and a clear strategy, The Good Bug is well-positioned to lead in key wellness categories as India’s nutraceuticals market continues to grow,” said Bhavani Rana, investment advisor to Susquehanna Asia VC.